107 related articles for article (PubMed ID: 28316082)
1. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
[TBL] [Abstract][Full Text] [Related]
3. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Bowen JM; Mayo BJ; Plews E; Bateman E; Wignall A; Stringer AM; Boyle FM; Keefe DM
Cancer Chemother Pharmacol; 2014 Sep; 74(3):617-27. PubMed ID: 25055934
[TBL] [Abstract][Full Text] [Related]
4. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
Secombe KR; Ball IA; Shirren J; Wignall AD; Finnie J; Keefe D; Avogadri-Connors F; Olek E; Martin D; Moran S; Bowen JM
Cancer Chemother Pharmacol; 2019 Mar; 83(3):531-543. PubMed ID: 30535958
[TBL] [Abstract][Full Text] [Related]
5. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
[TBL] [Abstract][Full Text] [Related]
10. Histomorphological and Immunohistochemical Study of Dacomitinib-Induced Ileal Mucositis in Rats with the Possible Protection by Baicalin.
Kandeel S; Estfanous RS
J Microsc Ultrastruct; 2023; 11(3):135-144. PubMed ID: 38025187
[TBL] [Abstract][Full Text] [Related]
11. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
[TBL] [Abstract][Full Text] [Related]
12. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.
Raja Sharin RNFS; Khan J; Ibahim MJ; Muhamad M; Bowen J; Wan Mohamad Zain WNI
Biomed Res Int; 2022; 2022():4165808. PubMed ID: 35800225
[TBL] [Abstract][Full Text] [Related]
13. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
14. Investigation of dacomitinib on reducing cell necrosis and enhancing cell apoptosis in C6 glioma rat model by MRI.
Chen WS; Hong L; Wang F; Li JJ
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30782784
[TBL] [Abstract][Full Text] [Related]
15. Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry.
Yamamoto Y; Saita T; Oka A; Kataoka H; Shin M
Acta Histochem Cytochem; 2019 Dec; 52(6):101-106. PubMed ID: 32001948
[TBL] [Abstract][Full Text] [Related]
16. Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice.
Chen Y; Zheng H; Zhang J; Wang L; Jin Z; Gao W
J Ethnopharmacol; 2016 Aug; 190():200-11. PubMed ID: 27240747
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Gibson RJ; Bowen JM; Alvarez E; Finnie J; Keefe DM
Chemotherapy; 2007; 53(5):360-9. PubMed ID: 17713326
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.
Mok T; Lee K; Tang M; Leung L
Future Oncol; 2014 Apr; 10(5):813-22. PubMed ID: 24799062
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
Brzezniak C; Carter CA; Giaccone G
Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
